As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer-reviewed and may be re-organised for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

jnc7911-sup-0001-FigureS1-S2-TableS1-S2.pdfapplication/PDF402K Table S1. Summary of CSF samples obtained from 4 different centres. Table S2. Summary of assay performance of the 3R- and 4R- tau iPCR assays. Figure S1. Development and optimisation of iPCR for 3R- and 4R- tau: Optimisation of RD3 (a) and RD4 (b) coating concentrations and sheep anti-tau DNA conjugate dilution factor for the 3R- (c) and the 4R- tau assays (d). Comparison of different artificial CSF ratio in sample dilution buffer in 3R-tau assay (e). Dilution series for 4R-tau in artificial CSF and sample dilution buffer, 4R-tau assays carried out in both sequential and combined incubations (f). Figure S2. CSF parallelism for 3R- (a) and 4R- tau (b) between buffer and CSFs; and the parallelism for 4R- tau (c) between artificial CSF and pooled clinical CSF.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.